EyePoint Pharmaceuticals Total Current Liabilities

EyePoint Pharmaceuticals (EYPT) currently reports a total current liabilities of $37M as of March 2026. That compares with $42M in the prior-year period — down 10.1% year over year. Use the charts on this page to explore EyePoint Pharmaceuticals's total current liabilities history and peer comparisons.

EyePoint Pharmaceuticals's total current liabilities decreased from $42M to $37M — a 10.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

EyePoint Pharmaceuticals reported $37M in total current liabilities as of March 2026. That compares with $42M in the prior-year period — down 10.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $37M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for EyePoint Pharmaceuticals, and consider following EYPT for alerts when major investors trade the stock.

EyePoint Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $37M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EYPT with unrelated industries.